Passage of pentobarbital and phenobarbital into bovine caprine milk after systemic administration

Breast-feeding and maternal drug use

Because drugs are almost never tested for use in lactating women before marketing, uncertainties about their safety for breast-fed infants often cause anxiety and unnecessary interruption of breast-feeding. Based on an understanding of mechanisms and principles of drug excretion into milk, we can rationally minimize the uncertainties. As described in this article, the infant exposure levels may be predicted using actual data on drug concentrations or even theoretic equations. Although the approach has to be rigorously tested in future studies, informed decisions on breast-feeding during maternal drug therapy are now within reach of resourceful health professionals. As more outcome data become available, remaining uncertainties will be addressed.

Analytical considerations for trace determinations of drugs in breast milk

Recent scientific and regulatory interest in lacteal excretion of drugs has prompted this review of bioanalytical sample preparation techniques for milk. The composition and properties of milk are reviewed, with emphasis on how the sample preparation is affected. The most important principals of mammary gland pharmacology, including protein binding, ion trapping and liquid solubility, are described. Because adequate milk volume is difficult to obtain from some smaller rodent species, special arrangements for sample collection, control preparation and assay standardization often need to be made. Several commonly-used sample preparation approaches for drugs in milk, including direct injection, dialysis and ultrafiltration, protein precipitation, liquid-liquid extraction, solid-phase extraction and immunoaffinity extraction. Have been reported with varying degrees of success. The advantages and disadvantages of each of these approaches is discussed.

Drug residue considerations for anesthetics and adjunctive drugs in food-producing animals

This article is a summary of residue concerns for anesthetics and anesthetic adjuncts used in food animals. The risks associated with residues of these drugs in food-producing animals, as well as the veterinarian's responsibility to reduce this risk, are discussed. The potential for residues and suggestions for prevention in each of the major anesthetic drug classes are described. Suggested withdrawal times are proposed for nonapproved drugs used off label. Each class of drug is summarized in the tables.

Modelling of the passage of drugs into milk

Pharmacokinetic modelling of plasma to milk transfer of drugs has assisted our understanding of the milk to plasma ratio (M/P) and pitfalls associated with it. The most useful way of measuring M/P ratios is, however, by model independent analysis. Physiological models have been proposed to enable the prediction of M/P ratios. The most accurate in prospective performance is the log-transformed phase distribution model. This model, developed by stepwise multiple linear regression analysis, also assists in the understanding of the relative contribution of the various physiological factors involved in the distribution of drugs into milk.

Drugs in human milk. Clinical pharmacokinetic considerations

Drugs ingested by a lactating mother would be expected to appear in human milk to some extent and be ingested by a breast-feeding infant. Drugs pass from maternal plasma into milk by passive diffusion and are distributed within the aqueous, protein and lipid phases of milk. Distribution into milk will be affected by physiochemical characteristics of the drug: acid-base characteristics, relative protein binding in plasma and milk, and lipid solubility, as well as milk composition. The milk-to-plasma concentration ratio is the most commonly quoted index of drug distribution into human milk. However, calculation of the daily infant dose of drug ingested in milk, and from this the dose in milk relative to the maternal dose on a weight-adjusted basis, is a more relevant indicator of infant exposure to a drug. This is particularly true for drugs with a high volume of distribution, for which only a small proportion of the mother's dose is contained within the plasma and available for distribution into milk. A better indication of infant exposure to a drug is the steady-state plasma drug concentration in a breast-feeding infant, the major determinants of which are the dose rate (via milk) and the oral availability and clearance in the infant. Although in neonates the rate of absorption may be different from adults, there is little evidence that its extent is significantly different. Clearance, however, is impaired in very young infants, particularly if premature. The decreased clearance would result in a proportional increase in steady-state plasma concentrations in the breast-feeding infant. Consideration of the dose ingested in milk and the approximate clearance in infants of different ages allows estimation of likely steady-state plasma concentrations in breast-feeding infants. From these considerations, recommendations regarding the safety of drugs during breast-feeding can be made. Drugs which are very toxic or have dose-independent toxicity should be considered separately. Recommendations regarding 'social' drugs such as nicotine, alcohol, caffeine and theobromine are particularly difficult, as doses are uncontrolled and vary variable.

Prediction of drug concentrations in human skim milk from plasma protein binding and acid-base characteristics

1. Protein binding in human skim milk of a series of seven drugs with diverse plasma protein binding and acid-base characteristics, was measured by ultrafiltration. 2. A mathematical relationship between plasma and skim milk unbound fractions was established using measured values from this study along with values from the literature. 3. The relationship enables prediction of unknown protein binding values of drugs in skim milk from known plasma protein binding values. 4. Knowledge of milk protein binding enables a more accurate assessment of total milk concentrations than is available from existing theory which is limited to prediction of unbound drug.

Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I)

Rational pharmacotherapy is dependent upon an understanding of the clinical pharmacokinetic and pharmacodynamic properties of the drugs employed. Although the available data on drug biodisposition and action in the neonate have increased considerably in the last few years, pharmacokinetic-pharmacodynamic interactions for many drugs remain poorly understood. The ontogeny of drug absorption, distribution, metabolism, and elimination are addressed in this review. Drug absorption from any site depends upon both the physicochemical properties of the drug and a variety of patient factors. Absorption of orally administered drugs may be affected by changes in gastric acidity and emptying time as well as by bile salt pool size, bacterial colonisation, and extraintestinal disease states such as congestive heart failure. Factors affecting drug absorption following intramuscular, percutaneous, and rectal administration are also discussed. Drug distribution in the neonate is influenced by a variety of important and predictable age-dependent factors. The developmental aspects of protein binding and body water compartments are described. Additionally, hepatic drug metabolism assumes an important role in understanding the pharmacokinetic and pharmacodynamic properties of many compounds. Certain biotransformation pathways, including hydroxylation by the P450 mono-oxygenase system and glucuronidation, demonstrate only limited activity at birth, while other pathways, such as sulphate or glycine conjugation, appear very efficient at birth. Elimination of drugs excreted unchanged in the urine is dramatically reduced in the newborn, compared with older infants and children, due to immaturity of both glomerular filtration and tubular secretory processes. The glomerular filtration rate remains markedly reduced prior to 34 weeks gestational age, increasing as a function of post-conceptual age until adult values are achieved by approximately 2.5 to 5 months of age. Tubular secretory capacity is also limited at birth, approaching adult values by approximately 7 months of age. Published reports describing the pharmacokinetics and pharmacodynamics of commonly used drugs in the neonatal period, as well as differences in drug biodisposition among premature infants, full term neonates, and older infants and children, are reviewed. Our recommendations for neonatal drug therapy are based upon a critical interpretation of these data, an understanding of fetal development and maturational processes, and an understanding of how disease states may affect drug biodisposition in the neonate.

Disposition of anesthetic and anesthetic-related agents in ruminants

Many factors may influence the actions and fates of anesthetic and anesthetic-related agents in ruminant animals. These considerations need to be taken into account when these drugs are employed clinically. Some of the major principles governing the disposition of CNS-active drugs are reviewed, with special emphasis on the uniqueness of ruminant animals. General pharmacokinetic considerations are also covered as a preamble to a commentary on the kinetic characteristics of anesthetic and anesthetic-related agents that are commonly used in domesticated ruminants.

Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences

The excretion of drugs in human breast milk is reviewed with regard to milk production, composition, feeding patterns and mechanisms of drug transfer into milk. Fundamental principles of breast milk excretion are used to construct a pharmacokinetic approach useful for the study of most drugs. An infant-modulated 3-compartment open model is proposed for drug distribution and elimination in the breast feeding woman. Milk/plasma drug concentration ratios are projected on the basis of pH partitioning. While some studies confirm these projections, other studies demonstrate a need to consider additional factors such as lipid solubility and protein binding characteristics of a drug in milk. Data are lacking for most drugs and hence dosing via milk or risk to the infant remains speculative. Very few pharmacokinetic studies of both milk and infant plasma were found. A review of selected drug classes cites available information as a basis for future studies. Few drugs are contraindicated in breast feeding women, but supportive data for either proscriptions or permissive statements are often lacking. A neglected but potentially serious infant risk--impaired behaviour and development--is discussed from the standpoint of emerging animal data. Conceptually valid and comprehensive studies on drug excretion in breast milk are needed if this valuable nutrient for infants is to be made available safely.

The dairy goat as a model in lactation studies

The dairy goat has been used widely in lactation research due in large part to availability, convenience in size and handling, economic considerations, and similarity to the cow as a ruminant species in general and metabolic processes. Considerable basic knowledge of lactation relating to all species has been derived from studies with goats. Although the gross composition of goat and cow milk is similar, significant differences reflect differing synthetic functions. Caution is necessary in using the goat as a model for the dairy cow where differences occur. Some are obvious such as the gross structure of the mammary gland and differing milk constituents. Others are more subtle, such as the susceptibility to metabolic diseases associated with lactation and differing rates of metabolism affecting transfer of dietary and administered materials into milk.